"After talking to some diabetics though they said it is too expensive to take all the time."
Er, not quite. The trial hasn't concluded yet, the FDA hasn't evaluated the New Drug Application (NDA) yet, so the company itself doesn't know pricing yet. Pricing information is CERTAINLY not public as it is considered a trade secret until approval, so your information is not accurate, ...however well intended.
Patients in the Investigational New Drug (IND) program have to pay for the drug themselves at $25/canister. This price is set by the FDA, not the company. The absorption rate while less than needles, is nearly on parity.
When healthy people eat there is an immediate release of insulin to begin the digestive process. Diabetics' insulin release is faulty. The insulin has to do its job then dissipate. Oral-Lyn replaces the missing insulin at meal time and has a short tail, meaning it leaves when it is suppose to. Hope this helps.
